XTNT Stock Forecast & Price Target

Xtant Medical Holdings is a medical technology company with a diverse portfolio of orthobiologics and spinal implant systems, generating a majority of its revenue in the United States. With recent product launches and a higher revenue guidance for fiscal year 2026, the company is well-positioned for growth. The recent sale of its Coflex, CoFix, and OUS business will allow Xtant to focus more on its core business of orthobiologics, potentially leading to improved profitability and market traction. However, competition, the need for additional capital, and a softer-than-expected procedure environment remain as risks. Despite these challenges, with shares trading at a substantial discount to peers, potential upside from product launches and increased distribution, and a goal to become a $150M-$200M revenue company, Xtant Medical Holdings has a positive outlook as a strong player in the spine and orthobiologics markets.

Xtant Medical Holdings is facing challenging times ahead as they continue to struggle with profitability and a significant decrease in revenue. Despite efforts to reduce debt and improve cash flow, the recent asset sale and changing business mix have not resulted in significant improvements. The company's focus on orthobiologics may improve their long-term potential, but for now, their financials and business composition make them a high-risk investment option.